These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4595073)

  • 1. Oxprenolol in hypertension.
    Marshall AJ; Barritt DW
    Br J Clin Pract; 1973 Sep; 27(9):337-40. PubMed ID: 4595073
    [No Abstract]   [Full Text] [Related]  

  • 2. [Oxprenolol in the treatment of essential arterial hypertension].
    Soto Rojas G
    Prensa Med Mex; 1976; 41(5-6):188-93. PubMed ID: 792867
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative study of the effects of oxprenolol versus propranolol in essential hypertension.
    Gavras I; Gavras H; Sullivan PC; Tifft CP; Chobanian AV; Brunner HR
    J Clin Pharmacol; 1979 Jan; 19(1):8-14. PubMed ID: 368088
    [No Abstract]   [Full Text] [Related]  

  • 4. [An example of an acceptable combination in the treatment of arterial hypertension].
    Menard J; Plouin PF; Gouin F; Corvol P; Milliez P
    Sem Hop; 1978 Feb; 54(4):201-6. PubMed ID: 208167
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of essential hypertension with oxprenolol and chlorthalidone in a fixed combination.
    Karachalios GN
    Int J Clin Pharmacol Res; 1983; 3(3):153-6. PubMed ID: 6679518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antihypertensive effect and adverse effects of treatment with beta-blocking agents].
    Andersson O; Berglund G; Bergman H; Cramér K; Fagerberg SE; Forsberg SA; Johnsen V; Lundkvist L; Rutle O; Sjolyst R
    Lakartidningen; 1975 Nov; 72(48):4738-40. PubMed ID: 1105030
    [No Abstract]   [Full Text] [Related]  

  • 7. Slow-Trasicor (sustained-release oxprenolol hydrochloride 160 mg) in the treatment of essential hypertension: a multicentre evaluation of 4,400 patients.
    Forrest WA
    Br J Clin Pract; 1977 Nov; 31(11):181-6. PubMed ID: 339937
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative study of oxprenolol and atenolol in the treatment of hypertension.
    Kamili MA; Allaqaband GQ; Ali G; Shah MY; Sheikh AS
    Indian Heart J; 1988; 40(6):471-4. PubMed ID: 3248806
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of oxprenolol plus chlorthalidone in fixed combination against chlorthalidone alone in mild to moderate essential hypertension; a clinical trial.
    Gruppillo P; Tomasi AM; Masoni A; Finzi C
    G Ital Cardiol; 1980; 10(4):476-9. PubMed ID: 7002694
    [No Abstract]   [Full Text] [Related]  

  • 10. [A multicenter clinical comparison study between Tevacor and Trasicor in hypertension].
    Shmueli H; Rosenfeld J
    Harefuah; 1986 Jun; 110(11):550-2. PubMed ID: 3533738
    [No Abstract]   [Full Text] [Related]  

  • 11. "24-hour blood pressure control" with sustained release oxprenolol 160mg plus cyclopenthiazide 0.25mg (Trasidrex) in general practice.
    Forrest WA; Bridgman KM; Ebbutt AF
    Br J Clin Pract; 1983; 37(11-12):385-8. PubMed ID: 6367794
    [No Abstract]   [Full Text] [Related]  

  • 12. [Advantages of a fixed association of oxprenolol-chlorthalidone, as opposed to chlorthalidone alone, in the treatment of chronic essential arterial hypertension].
    Baronchelli A; Agosta R; Verdecchia P; Bichisao E
    Clin Ter; 1981 Apr; 97(1):63-9. PubMed ID: 7026137
    [No Abstract]   [Full Text] [Related]  

  • 13. Bethanidine and oxprenolol in hypertension--a study in combination therapy.
    Rowlands G; McConachie NA; Currie WJ
    Practitioner; 1977 Jul; 219(1309):105-8. PubMed ID: 329261
    [No Abstract]   [Full Text] [Related]  

  • 14. [Multicenter study with a fixed combination of oxprenolol/chlorthalidone in essential arterial hypertension].
    Albanesi Filho FM; Benchimol AB
    Arq Bras Cardiol; 1980 May; 34(5):409-14. PubMed ID: 7006573
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of refractory hypertension with a fixed oxprenolol/chlorthalidone/hydralazine combination. Results of an open multicenter trial].
    Krönig B; Wendt G
    Med Welt; 1983 Sep; 34(35):941-4. PubMed ID: 6355745
    [No Abstract]   [Full Text] [Related]  

  • 16. [Evaluation of the hypotensive effect of slow-release Trasicor].
    Cybulska I; Brym E
    Kardiol Pol; 1982; 25(4):329-35. PubMed ID: 6755030
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of three different methods of monitoring unwanted effects during antihypertensive therapy.
    Borghi C; Pallavini G; Comi D; Grillo G; Lombardo M; Mantero O; Minetti L; Selvini A; Suppa G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):324-8. PubMed ID: 6378807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the effects of the slow release formulations of metoprolol and oxprenolol in hypertension.
    Comerford MB; Besterman EM
    Ann Clin Res; 1982 Feb; 14(1):27-31. PubMed ID: 7137874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of combination of guanethidine and oxprenolol in hypertension.
    Pearson RM; Bending MR; Bulpitt CJ; George CF; Hole DR; Williams FM; Breckenridge AM
    Br Med J; 1976 Apr; 1(6015):933-6. PubMed ID: 773486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of antihypertensive efficacy: propranolol versus oxprenolol in accelerated hypertension.
    Fernandez PG; Sharma JN; Galway AB; Kim BK; Granter S; Zachariah PK
    Pharmatherapeutica; 1982; 3(3):153-6. PubMed ID: 6752962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.